GE Healthcare Life Sciences Announces New US Headquarters in Massachusetts - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

GE Healthcare Life Sciences Announces New US Headquarters in Massachusetts


GE Healthcare Life Sciences has announced that it will open a 160,000-sq ft facility in Marlborough, Mass., as the new headquarters for its US operations.  The $21 million facility will employ more than 500 GE Healthcare Life Sciences employees.

The company reports that the investment will transform a currently unoccupied space into state-of-the-art labs, customer application facilities, and office space to complement GE Healthcare Life Sciences’ existing manufacturing capability in Westborough, Mass. The facility will consolidate GE Healthcare Life Sciences’ US East Coast presence. When fully operational, the facility will bring more than 220 highly qualified new job opportunities to the area, including highly skilled positions such as lab technicians, biologists, medical doctors, process engineers, and customer service representatives.

GE Healthcare Life Sciences’ $4 billion business has more than 11,500 employees in more than 100 countries. The new US headquarters will house employees from across the Life Sciences business, including its research, bioprocessing, medical imaging, in vitro diagnostics, and services segments. Recruitment has begun with the site scheduled to open in Spring 2015.

 Source: GE Healthcare Life Sciences

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here